Introduction
============

Osteoporosis, the most common chronic metabolic bone disease, is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fractures [@B1]. It is considered a global epidemic since it has been estimated than more than 200 million people are suffering from osteoporosis [@B2]. In addition, osteoporosis is associated with decreased quality of life and increased disability-adjusted life span [@B3], [@B4]. Moreover, it implies a significant health care cost to insurance systems of countries [@B5]. Osteoporosis is determined by the effects of several genes, which exert a relatively modest effects, and modifiable variables such diet and physical activity [@B6].

Advances in the knowledge of the genetics of osteoporosis will allow individual genetic profiles to become a common routine practice, facilitating more personalized health care [@B7]. Moreover, genetic screening will be increasingly relevant in the disease prevention and early treatment [@B8]. Due to the increased prevalence of osteoporosis and direct health care cost of osteoporosis-related fractures, there is a growing interest in identifying genetic markers associated with osteoporosis in order to develop genetic screening strategies. To date, most candidate gene and genome-wide association studies (GWAS) examining the genetic factors influencing bone phenotype parameters have been focused on BMD assessed by DXA [@B9], [@B10]. One of the most powerful studies, a meta-analysis pooling five GWAS, revealed novel strong associations between genetic variants in *ZBTB40* (zinc finger- and BTB domain-containing 40*), SP7 (Osterix)* (Sp7 transcription factor 7) and *AKAP11* (A-kinase anchoring protein 11) genes and BMD at femoral neck and lumbar spine [@B9] that have been confirmed in further studies [@B11]-[@B16].

Quantitative ultrasound (QUS) is considered a valuable screening tool for assessing bone status in clinical practice [@B17]. Compared to dual X-ray absorptiometry (DXA), QUS offer more accessibility to the population since is a non-invasive, radiation-free, transportable and low-cost device. Calcaneal QUS provides information on the main constituents of bone health, bone quantity (bone mass) and bone quality (bone microarchitecture) [@B18]. In addition, a meta-analysis of prospective studies revealed that calcaneal QUS predicts the risk of different types of fracture independently of DXA [@B19].

Familial studies have reported that calcaneal QUS parameters are under strong genetic control, with a suggested heritability of 74% [@B20]. In spite of this fact, a scarce number of studies have examined genetic factors associated with ultrasonography bone parameters [@B21]. A few studies have confirmed that different genetic BMD factors such as *WNT16* are also associated with QUS parameters [@B21]-[@B24]. However, it has not been investigated if *ZBTB40, SP7* and *AKAP11* are also associated with other skeletal traits such as calcaneal QUS.

On the other hand, peak bone mass (PBM), defined as the level of bone mass achieves at the end of the grow period, is known to be influenced by both genetic and environmental factors [@B25], [@B26]. Twins and family studies suggested that 60-80% of the variance of the PBM is genetically determined [@B27]. Since it has been reported that a 10% increase in PBM may reduce the risk of osteoporotic fractures in older adults by 50% [@B28], the achievement of PBM in early ages is especially important in the prevention of osteoporosis. Therefore, there is a growing interest in investigating the genetic variants that influence bone status at early ages through primary effects on growth.

On this context, to determine if the associations between *ZBTB40 (*rs7524102, rs6426749)*, SP7* (rs2016266) and *AKAP11 (*rs9533090) and BMD was specific for this bone trait, for the first time, we have tested for associations between these genetic markers and calcaneal QUS parameter in a population of young adults.

Material and methods
====================

Subject characteristics
-----------------------

A cross-sectional study was conducted on 550 Spanish healthy individuals of European ancestry (381 females and 169 males, median age 20.46±2,69). A detailed medical history was obtained for all subjects. In particular, those with a history of bone disease, metabolic or endocrine diseases, hormonal contraceptive therapy on medication that could affect bone mass were excluded from the study. Signed informed consent was obtained from all participants individually, the study was approved by local ethics committees, and it was conducted in accordance with the Declaration of Helsinki.

Bone assessment
---------------

The CUBA clinical ultrasound bone densitometer (McCue Ultrasonic Limited, Compton, Winchester, UK) was used to perform the QUS measurements. Bone mass was assessed through broadband ultrasound attenuation parameter (BUA, dB/MHz) on the right calcaneus. The apparatus was calibrated on a daily basis using a physical phantom to control its long-term stability.

Covariates
----------

Weight to the nearest 0.1 kg was recorded using a Body Composition Analyser (TANITA BC-418MA), and height was measured to the nearest 0.1 cm using a Harpenden stadiometer. Both measurements were taken without shoes on. The same trained research assistant performed all the measurements. Physical activity were determined using the self-administered International Physical Activity Questionnaire (IPAQ) [@B29]. Dietary calcium intake (DCI) was assessed using the 72-hour recall method, considering intakes on Thursday, Friday and Saturday. Food records were converted to nutrient intake using a computerized nutrient analysis program (Nutriber 1.1.5).

SNP selection and genotyping
----------------------------

Saliva samples for DNA extraction were collected from the study participants using the OG-500 Collection Kit (DNA Genotek Inc, Ontario, Canada). The DNA was isolated from the saliva samples according to the manufacturer\'s protocol. We selected SNPs in *ZBTB40 (*rs7524102, rs6426749)*, SP7* (rs2016266) and *AKAP11 (*rs9533090) as genetic markers based on their previously identified genome-wide strong association with lumbar spine and/or femoral neck BMD in a meta-analysis pooling five GWAS [@B9]. Genotyping was performed at the Genomic and Genotyping Unit in the GENyO Center (Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research) using TaqMan SNP Genotyping Assays (Applied Biosystems, Foster City, CA). TaqMan SNP genotyping plates were custom designed including four predesigned genotyping assays for each of the four selected SNPs. Standard cycling conditions were used, as recommended by the manufacturer. Thermal cycling and fluorescence detection were performed using the QuantStudio 12K Flex Real-Time PCR System (Applied Biosystems). The average missing rate for the genotyping assays was 1.54%, with a range from 1.27% to 1.81%. To guarantee the accuracy of genotyping, duplicate samples and negative controls were included in all genotyping arrays, presenting 100% identical genotypes.

Statistical analysis
--------------------

The Haploview software (Broad Institute of MIT and Harvard) was used to calculate allele frequencies and verify that the genotype data were in Hardy-Weinberg equilibrium (HWE). Linear regression analysis was used to analyze the relationships between the SNPs and calcaneus ultrasounds adjusted for age, sex, weight, height, physical activity, and calcium intake. The results are reported as a percentage change (β) in the standard deviation (SD) with 95 % confidence intervals (95 % CI). The most conservative method (Bonferroni correction) was applied to correct for multiple comparisons. Values of less than 0.05 were considered statistically significant. The cut-off value for significance was set as p=0.05/4=0.012. All statistical analyses were performed using SPSS version 20.0 (SPSS, Chicago, IL, USA). Statistical power of the study was estimated using Quanto version 1.2 software (Department of Preventive Medicine, University of Southern California).

Results
=======

The basic characteristics of the 550 study subjects are shown in Table [1](#T1){ref-type="table"}. The average BUA value for the total population was 82.22±26.67 dB/Mhz. This value was similar to that previously observed for young adults [@B30], [@B31]. Mean weight was 63.90 ±12.88 63.7 kg; mean height was 1.67±0.08 m. Calcium intake averaged 800.157 ±349.90 mg/day. PA averaged 2863.63 ±3876.92 MET/min.

The location, genotype, and allele frequency of the SNPs selected as genetic markers are listed in Table [2](#T2){ref-type="table"}. The observed MAF of all the SNPs examined was comparable to those reported by the European-CEU population panel. The genotype frequencies were as follows: rs7524102 (AA 67.5%; AG; 27.5%; GG 5.0%), rs6426749 (GG 59.0%; GC 37.0%; CC 4.0%), rs2016266 (AA 40.65%; AG 43.4%; GG 16.0%) and rs9533090 (CC 33.5%; CT 45.5%; TT 21.0%). None of the SNPs failed the missingness test (genotyping \>0.05) or frequency test (MAF \<0.01) and were observed to be in HWE.

Linear regression analysis revealed that rs7524102 and rs6426749 in *ZBTB40,* and rs9533090 in *AKAP11* were significantly associated with the calcaneal QUS parameter after adjustments for age, sex, weight, height, physical activity, and calcium intake (p=0.038, p=0.012 and p=0.008, respectively) (Table [3](#T3){ref-type="table"}). After applying the Bonferroni correction for multiple testing (p=0.012), only the association of rs9533090 in *AKAP11* remained significant. For the rs2016266 SNP in *SP7,* no significant association was observed after adjusting for confounding variables (Table [3](#T3){ref-type="table"}).

Discussion
==========

This study involved a population of well-characterized young healthy Caucasian individuals in which the association between *ZBTB40, SP7* and*AKAP11* genes and bone status assessed by calcaneal QUS were examined for the first time. Our results revealed that the rs9533090 polymorphism in *AKAP11* seems to be as a genetic factor influencing calcaneal QUS parameter during youth.

*AKAP11* has been reported to be a gene conferring susceptibility to osteoporosis [@B9], [@B11], [@B12], [@B32], [@B33]. In particular, the rs9533090 SNP has been associated with BMD assessed by DXA in large-scale meta-analysis of GWAS at the genome wide significant level [@B9], [@B11], [@B12]. In fact, this SNP reached the top p value (p=5.4x10^-25^) at lumbar spine BMD of the known loci identified by Rivadeneira et al. [@B9]. In this line, for the first time, in this study we identified a significant association of the rs9533090 SNP with the calcaneus ultrasound parameter even after applying Bonferroni correction (p=0.008). This SNP is located on chromosome 13, about 8 Kb upstream of *AKAP11* (A kinase anchor protein 11) and 35 Kb downstream of *DGKH* (diacylglycerol kinase, eta).*AKAP11* codifies for a protein expressed at high levels through spermatogenesis and in mature sperm that binds to protein kinase A [@B34]. A recent work in which gene expression profile of *AKAP11* was examined in primary mouse osteoblasts undergoing differentiation, identified a constant expression during osteoblast maturation [@B32]. Hence, impaired signaling through this receptor due to genetic variation in the *AKAP11* gene might exert a role in bone mass regulation. To date, the functional relevance of the rs9533090 SNP has not been investigated. Considering its location upstream of the gene, it could be hypothesized that this polymorphism may interfere the activity of regulatory elements that control the function of the *AKAP11* gene. Another possibility that should be considered is that the rs9533090 SNP might be in linkage disequilibrium with the real causing variant. Thus, to fully characterize the molecular mechanisms underlying the association of *AKAP11* gene with bone phenotypes, further studies are required to identify the real causing variant and its influence in the gene activity or expression.

On the other hand, we did not observe evidence of association at any of the other loci investigated (rs7524102 and rs6426749 in *ZBTB40* gene and rs2016266 in *SP7*), and calcaneal QUS after Bonferroni correction. Thus, according to our findings it could be suggested that they do not play a major role in bone status during early adulthood. Previous candidate gene association, GWAS and meta-analysis of GWAS studies investigating these genetic markers have reported significant associations with BMD at different skeletal sites in European and Asian populations [@B9], [@B16], [@B35]-[@B40]. Based on these observations, and in previous findings from our and other researchers it may possible to hypothesize that some genetic markers for QUS and BMD may be the same, while others would be different. For example, previous evidence have shown that *VDR* genetic markers are associated with BMD [@B41], [@B42] but no for calcaneal ultrasound parameters [@B21], [@B43]. Contrary, *WNT16* gene has demonstrated to influence both BMD [@B24] and QUS [@B21]-[@B23]. In addition, the observed differences may have been due at least in part to age differences, given that most previous work have conducted among older adults, mainly postmenopausal women [@B35], [@B37], [@B38] or mixed population range in age from 18 to 96 years [@B9], and our study comprised a well-characterized cohort of young adults.

This study has some limitations; one is that the cross-sectional design does not allow determination of a causal relationship. In addition, it is difficult to completely exclude the possibility that the lack of association observed in *ZBTB40* and*SP7* SNPs could likely be due to inadequate power (i.e., modest sample size). Power calculations showed that, considering the BUA mean observed in our population (82.22±26.67), MAFs of 0.18-0.44, 550 individuals, and a 5% type I error threshold, there was 50% power to detect increments in the mean using an additive genetic model. Therefore, further studies conducted among larger samples sizes of young adults would be useful to confirm our preliminary results. Another limitation of the present study is that since we looked at only four SNPs that had been previously associated with BMD, we did not cover all the genetic variation in the selected genes. Hence, other regions of these genes might be involved in regulating calcaneal QUS in early adulthood.

In conclusion, our study has provided evidence the *AKAP11* gene (rs9533090) influences QUS trait in a population of Caucasian young adults. The rs9533090 SNP may be considered a factor affecting peak bone mass acquisition. This advance in knowledge about the genetic markers with which to assess bone status at early ages is crucial to optimize bone health and prevent osteoporosis later in life. Since this study is the first to investigate the associations between genetic markers in *ZBTB40, SP7* and *AKAP11* genes and calcaneal QUS, these findings require replication in independent populations. If confirmed, further molecular studies molecular studies are warranted to understand the underlying mechanisms responsible for this association.
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###### 

Characteristics of the study population.

  Characteristic                  Means±SD
  ------------------------------- ------------------
  N                               550
  Age (years)                     20.46±2.69
  Height (m)                      1.67 ±.08
  Weight (kg)                     63.90 ±12.88
  BMI (kg/m^2^)                   22.70 ±3.75
  Calcium intake (mg/day)         800.157 ±349.90
  Physical activity (MET/min)\*   2863.63 ±3876.92
  Heel ultrasound BUA (dB/Mhz)    82.22±26.67

Data are shown as mean±SD.

\*The calculation of MET-hours is described in methods section.

BMI body mass index, BUA broadband ultrasound attenuation.

###### 

Overview of the selected SNPs, minor allele frequency (MAF) and Hardy-Weinberg Equilibrium (HWE).

  Closet gene   Locus   SNP         Allele\*   MAF in this study   MAF HapMap CEU   HWE (p)
  ------------- ------- ----------- ---------- ------------------- ---------------- ---------
  *ZBTB40*      1p36    rs7524102   A/g        0.18                0.18             0.07
  *ZBTB40*      1p36    rs6426749   c/G        0.22                0.12             0.15
  *SP7*         12q13   rs2016266   A/g        0.37                0.33             0.08
  *AKAP11*      13q14   rs9533090   t/C        0.43                0.43             0.11

\*Capital letter indicates the major allele and small letter indicates the minor allele.

###### 

Linear regression analysis results for the association of the selected SNPs with BUA.

  Closet gene   SNP         Heel BUA (Db/MHz)         
  ------------- ----------- ------------------------- ---------
  *ZBTB40*      rs7524102   0.087 (0.215, 7.785)      0.038
  *ZBTB40*      rs6426749   0.107 (1.171, 9.230)      0.012
  *SP7*         rs2016266   0.16 (-2.529, 3.711)      0.710
  *AKAP11*      rs9533090   -0.117 (-7.813. -1.155)   0.008\*

Beta represents the regression coefficient

Adjusted for age, sex, weight, height, physical activity and calcium intake.

\*Associations withstanding Bonferroni correction are indicated with asterisks.
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